Central India Chronicle

Oncolytic Virus Cancer Therapy Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | DNAtrix, Nouscom, Astellas Pharma, Transgene

 Breaking News
  • No posts were found

Oncolytic Virus Cancer Therapy Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | DNAtrix, Nouscom, Astellas Pharma, Transgene

May 18
03:40 2023
Oncolytic Virus Cancer Therapy Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | DNAtrix, Nouscom, Astellas Pharma, Transgene
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Oncolytic Virus Cancer Therapy pipeline constitutes key companies continuously working towards developing Oncolytic Virus Cancer Therapy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Oncolytic Virus Cancer Therapy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Oncolytic Virus Cancer Therapy Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Oncolytic Virus Cancer Therapy Market.

 

Some of the key takeaways from the Oncolytic Virus Cancer Therapy Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Oncolytic Virus Cancer Therapy treatment therapies with a considerable amount of success over the years. 
  • Oncolytic Virus Cancer Therapy companies working in the treatment market are DNAtrix, Nouscom, Astellas Pharma, Transgene, Istari Oncology, Targovax, Oncolytics Biotech, CG Oncolgy, Oncolys Biopharma, Transgene, MedImmune, and others, are developing therapies for the Oncolytic Virus Cancer Therapy treatment 
  • Emerging Oncolytic Virus Cancer Therapy therapies such as – DNX 2440, NOUS PEV, ASP 9801, TG 6002, PVS-RIPO, DNX-2401, ONCOS 102, Pelareorep, CG0070, OBP-301, TG6002, MEDI5395, Tasadenoturev, and others are expected to have a significant impact on the Oncolytic Virus Cancer Therapy market in the coming years.   
  • In January 2022, Affibody AB (“Affibody”) and Lokon Pharma AB established a partnership to combine oncolytic viruses with Affibody® compounds
  • In April 2022, New preclinical results will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 (April 8–13), according to an announcement from OncoMyx Therapeutics. The studies shown at AACR 2022 show that the myxoma virus from OncoMyx, which is multi-armed with IL-12 and decorin, infects and kills human multiple myeloma cells in vitro, and exhibits dose-responsive effectiveness after intravenous (IV) injection in a mouse model of multiple myeloma
  • In December 2021, AstraZeneca exercised its first licence option for an Invir.IOTM oncolytic virus (OV) created as a result of their ongoing OV collaboration, Transgene reported. Transgene received a $8 million payment from AstraZeneca as a result of the exercise of this option for an OV, which involved integrating an unidentified transgene.
  • In December 2021, A Phase 1b clinical trial using STI-1386, also known as SeprehvecTM, called “Dose Escalation Study of the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Patients with Relapsed or Refractory Solid Tumours” has been given the green light by the U.S. Food and Drug Administration (FDA)

 

Oncolytic Virus Cancer Therapy Overview

Oncolytic virus (OV) cancer therapies are virus-based treatment modalities that infect and kill cancer cells, and by releasing tumor-specific antigens, also serve as an in situ cancer vaccine. Myxoma virus and reovirus are two examples of viruses that naturally target tumour cells while being nonpathogenic to healthy human cells.

 

Get a Free Sample PDF Report to know more about Oncolytic Virus Cancer Therapy Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021

 

Emerging Oncolytic Virus Cancer Therapy Drugs Under Different Phases of Clinical Development Include:

  • DNX 2440: DNAtrix
  • NOUS PEV: Nouscom
  • ASP 9801: Astellas Pharma
  • TG 6002: Transgene
  • Olvi-Vec: Genelux Corporation
  • CAN-2409: Candel TherapeuticsCG0070: CG Oncology
  • PVS-RIPO: Istari Oncology
  • SND005: Jiangsu Sinorda Biomedicine
  • DNX-2401: DNAtrix
  • VCN-01: VCN Biosciences
  • ONCOS 102: Targovax
  • Pelareorep: Oncolytics Biotech
  • CG0070: CG Oncolgy

 

Route of Administration

Oncolytic Virus Cancer Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intranasal
  • Intravenous
  • Oral
  • Oral/Intravenous
  • Parenteral
  • Subcutaneous
  • Subcutaneous/Intramuscular

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Oncolytic Viruse

 

Oncolytic Virus Cancer Therapy Pipeline Therapeutics Assessment

  • Oncolytic Virus Cancer Therapy Assessment by Product Type
  • Oncolytic Virus Cancer Therapy By Stage and Product Type
  • Oncolytic Virus Cancer Therapy Assessment by Route of Administration
  • Oncolytic Virus Cancer Therapy By Stage and Route of Administration
  • Oncolytic Virus Cancer Therapy Assessment by Molecule Type
  • Oncolytic Virus Cancer Therapy by Stage and Molecule Type

 

DelveInsight’s Oncolytic Virus Cancer Therapy Report covers around 5+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Oncolytic Virus Cancer Therapy product details are provided in the report. Download the Oncolytic Virus Cancer Therapy pipeline report to learn more about the emerging Oncolytic Virus Cancer Therapy therapies

 

Some of the key companies in the Oncolytic Virus Cancer Therapy Therapeutics Market include:

Key companies developing therapies for Oncolytic Virus Cancer Therapy are – Lokon Pharma, Merck, Wuhan Binhui Biotechnology, CG Oncology, Oncolys Biopharma, Replimune, Transgene, Sorrento Therapeutics, ORCA Therapeutics, TILT Biotherapeutics, BioEclipse Therapeutics, Oncolytics Biotech, Oncorus, DNAtrix, OncoMyx Therapeutics, Vyriad, Boehringer Ingelheim, IconOVir Bio, Imugene, Turnstone Biologics, Immvira Pharma, SillaJen Biotherapeutics, Advantagene, Nouscom, TOT Biopharm, Elicera Therapeutics, Takeda, Candel Therapeutics, Valo Therapeutics, Tessa Therapeutics, PsiOxus Therapeutics, KaliVir Immunotherapeutics, Oncos Therapeutics, Mustang Bio, Takara Bio, Vaxiion Therapeutics, Synthetic Biologics, Calidi Biotherapeutics, Genelux Corporation, Shanghai Sunway Biotech, BioInvent International AB, Guizhou Sinorda Biomedicine, EpicentRx, Hookipa Pharma Inc., Imvaq Therapeutics, Seneca Therapeutics, AmunBio, Orgenesis, Protheragen, Astellas Pharma, MedImmune LLC, Istari Oncology, Inc., Treovir LLC, and others.

 

Oncolytic Virus Cancer Therapy Pipeline Analysis:

The Oncolytic Virus Cancer Therapy pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Oncolytic Virus Cancer Therapy with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Oncolytic Virus Cancer Therapy Treatment.
  • Oncolytic Virus Cancer Therapy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Oncolytic Virus Cancer Therapy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Oncolytic Virus Cancer Therapy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Oncolytic Virus Cancer Therapy drugs and therapies

 

Oncolytic Virus Cancer Therapy Pipeline Market Drivers

  • Increase in the number of patients with cancers, rising need for advanced and effective cancer therapeutics for improved quality of life are some of the important factors that are fueling the Oncolytic Virus Cancer Therapy Market.

 

Oncolytic Virus Cancer Therapy Pipeline Market Barriers

  • However, lack of development, scaleup and commercialization resources available to developers, lack of awareness about the new class of anticancer immunotherapy and other factors are creating obstacles in the Oncolytic Virus Cancer Therapy Market growth.

 

Scope of Oncolytic Virus Cancer Therapy Pipeline Drug Insight    

  • Coverage: Global
  • Key Oncolytic Virus Cancer Therapy Companies: DNAtrix, Nouscom, Astellas Pharma, Transgene, Istari Oncology, Targovax, Oncolytics Biotech, CG Oncolgy, Oncolys Biopharma, Transgene, MedImmune, and others
  • Key Oncolytic Virus Cancer Therapy Therapies: DNX 2440, NOUS PEV, ASP 9801, TG 6002, PVS-RIPO, DNX-2401, ONCOS 102, Pelareorep, CG0070, OBP-301, TG6002, MEDI5395, Tasadenoturev, and others
  • Oncolytic Virus Cancer Therapy Therapeutic Assessment: Oncolytic Virus Cancer Therapy current marketed and Oncolytic Virus Cancer Therapy emerging therapies
  • Oncolytic Virus Cancer Therapy Market Dynamics: Oncolytic Virus Cancer Therapy market drivers and Oncolytic Virus Cancer Therapy market barriers 

 

Request for Sample PDF Report for Oncolytic Virus Cancer Therapy Pipeline Assessment and clinical trials

 

Table of Contents

1

Oncolytic Virus Cancer Therapy Report Introduction

2

Oncolytic Virus Cancer Therapy Executive Summary

3

Oncolytic Virus Cancer Therapy Overview

4

Oncolytic Virus Cancer Therapy- Analytical Perspective In-depth Commercial Assessment

5

Oncolytic Virus Cancer Therapy Pipeline Therapeutics

6

Oncolytic Virus Cancer Therapy Late Stage Products (Phase II/III)

7

Oncolytic Virus Cancer Therapy Mid Stage Products (Phase II)

8

Oncolytic Virus Cancer Therapy Early Stage Products (Phase I)

9

Oncolytic Virus Cancer Therapy Preclinical Stage Products

10

Oncolytic Virus Cancer Therapy Therapeutics Assessment

11

Oncolytic Virus Cancer Therapy Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Oncolytic Virus Cancer Therapy Key Companies

14

Oncolytic Virus Cancer Therapy Key Products

15

Oncolytic Virus Cancer Therapy Unmet Needs

16 

Oncolytic Virus Cancer Therapy Market Drivers and Barriers

17

Oncolytic Virus Cancer Therapy Future Perspectives and Conclusion

18

Oncolytic Virus Cancer Therapy Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services